300199 翰宇药业
已收盘 11-22 15:00:00
资讯
新帖
简况
翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！
市场资讯 · 11-17
翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
格隆汇 · 11-17
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
美港电讯 · 11-13
翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
证券之星 · 11-13
翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升
证券之星 · 10-31
翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升
翰宇药业最新公告：第三季度净利润亏损2444.68万元
证券之星 · 10-29
翰宇药业最新公告：第三季度净利润亏损2444.68万元
翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可
证券之星 · 10-29
翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可
翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液
证券之星 · 10-17
翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液
A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。
美港电讯 · 10-17
A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。
翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理
智通财经 · 10-14
翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理
翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号
证券之星 · 09-25
翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号
翰宇药业：司美格鲁肽原料药获得DMF备案号
美港电讯 · 09-25
翰宇药业：司美格鲁肽原料药获得DMF备案号
翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号
智通财经 · 09-25
翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号
翰宇药业(300199.SZ)：艾塞那肽注射液获批上市 其用于改善2型糖尿病患者的血糖控制
智通财经网 · 09-18
翰宇药业(300199.SZ)：艾塞那肽注射液获批上市 其用于改善2型糖尿病患者的血糖控制
翰宇药业最新公告：艾塞那肽注射液获批上市
证券之星 · 09-18
翰宇药业最新公告：艾塞那肽注射液获批上市
翰宇药业：司美格鲁肽注射液减重三期临床研究方案近日公示
美港电讯 · 09-06
翰宇药业：司美格鲁肽注射液减重三期临床研究方案近日公示
翰宇药业：United Bank of Switzerland、Toronto-Dominion Asset Management等多家机构于9月5日调研我司
证券之星 · 09-05
翰宇药业：United Bank of Switzerland、Toronto-Dominion Asset Management等多家机构于9月5日调研我司
翰宇药业：生长抑素原料药获CEP证书 有利于海外市场拓展
中国财富通 · 09-04
翰宇药业：生长抑素原料药获CEP证书 有利于海外市场拓展
翰宇药业(300199.SZ)：生长抑素原料药获得CEP证书
智通财经 · 09-04
翰宇药业(300199.SZ)：生长抑素原料药获得CEP证书
先声再明引进第三代ALK抑制剂，步长制药长效 EPO 药物报上市，翰宇药业 GLP1R 激动剂启动肥胖 III 期临床
医药经济报 · 09-03
先声再明引进第三代ALK抑制剂，步长制药长效 EPO 药物报上市，翰宇药业 GLP1R 激动剂启动肥胖 III 期临床
暂无数据
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":11.72,"timestamp":1732258992000,"preClose":12.58,"halted":0,"volume":42310751,"delay":0,"floatShares":706000000,"shares":883000000,"eps":-0.4168,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.86,"latestTime":"11-22 15:00:00","open":12.56,"high":12.61,"low":11.69,"amount":511000000,"amplitude":0.0731,"askPrice":11.72,"askSize":392,"bidPrice":11.71,"bidSize":1527,"shortable":0,"etf":0,"ttmEps":-0.4168,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":12.58,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":13.84,"lowLimit":11.32,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"pbRate":15.72,"roa":"--","roe":"--","epsLYR":-0.58,"committee":0.726691,"marketValue":10352000000,"floatMarketCap":8278000000,"peRate":-28.119002,"changeRate":-0.0684,"turnoverRate":0.0599,"status":1},"requestUrl":"/m/hq/s/300199/tweets","defaultTab":"tweets","newsList":[{"id":"2484683573","title":"翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！","url":"https://stock-news.laohu8.com/highlight/detail?id=2484683573","media":"市场资讯","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484683573?lang=zh_cn&edition=full","pubTime":"2024-11-17 17:02","pubTimestamp":1731834120,"startTime":"0","endTime":"0","summary":" 自称“中国合成多肽第一股”的翰宇药业举报前总裁挪用资金一案获终审判决，公司原董事、高级管理人员袁建成犯挪用资金罪，判处有期徒刑三年六个月。 翰宇药业表示，案件为公司内部自查发现并向公安机关报案，袁建成已于2019年8月从公司离职，自涉嫌犯罪被公安机关采取刑事强制措施之后，公司已经根据相关会计准则计提了相关费用。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-11-17/doc-incwkiim4503870.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-11-17/doc-incwkiim4503870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0188","BK0077","BK0070","BK0239","300199"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"us","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0077","BK4585","LU2148510915.USD","LU0405327494.USD","BK0201","BK0028","BK0183","BK0251","LU1064131003.USD","LU1093756168.USD","LU1093756325.SGD","LU0405327148.USD","LU2488822045.USD","600276","300003","LU1328615791.USD","NVO","688117","BK0239","BK0114","BK0188","BK0012","IE00BKVL7J92.USD","BK0042","BK4588","002821","BK0196","BK0070","01801","BK0060","BK0113","603456","BK0132","LU0154236417.USD","IE00BZ1G4Q59.USD","300199","BK4007","LU1064130708.USD","688076","BK4532"],"gpt_icon":1},{"id":"2483071625","title":"翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071625","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071625?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:20","pubTimestamp":1731493244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0077","300199","BK0239","BK0188","BK0028","BK0070"],"gpt_icon":0},{"id":"2483071458","title":"翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071458","media":"证券之星","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071458?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:20","pubTimestamp":1731493210,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司原董事、高级管理人员袁建成犯挪用资金罪一案，已收到广东省深圳市中级人民法院的终审裁定。袁建成因利用职务便利，挪用公司资金1685万元归个人使用，被判处有期徒刑三年六个月。该案已审结。袁建成所涉犯罪行为发生在六年前，且其已于2019年8月从公司离职。公司已根据相关会计准则计提了相关费用。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0077","BK0028","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2479760039","title":"翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479760039?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:39","pubTimestamp":1730327993,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2024年三季报。截至本报告期末，公司营业总收入3.75亿元，同比下降6.56%，归母净利润-3480.56万元，同比上升80.72%。本报告期翰宇药业短期债务压力上升，流动比率达0.62。本次财报公布的各项数据指标表现一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100009286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300199","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2479032664","title":"翰宇药业最新公告：第三季度净利润亏损2444.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479032664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479032664?lang=zh_cn&edition=full","pubTime":"2024-10-29 19:41","pubTimestamp":1730202060,"startTime":"0","endTime":"0","summary":"翰宇药业发布2024年第三季度报告，前三季度实现营业收入3.75亿元，同比下降6.56%；归属于上市公司股东的净利润亏损3480.56万元。第三季度实现营业收入1.19亿元，同比增长56.67%；归属于上市公司股东的净利润亏损2444.68万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900036873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2479472927","title":"翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2479472927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479472927?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:50","pubTimestamp":1730199012,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司产品“醋酸阿托西班注射液”获得泰国食品药品监督管理局下发的《药品注册证书》，获得了泰国的上市许可。该药品适用于有早产指征的妊娠妇女，用于推迟即将出现的早产。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900035002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","300199","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2476111022","title":"翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2476111022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476111022?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:31","pubTimestamp":1729161062,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司收到美国合作方Hikma的采购需求订单，其拟向公司采购金额为1173.60万美元（约合人民币0.84亿元（含税））的利拉鲁肽注射液（仿制药）。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700027969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0077","300199","BK0188","BK0028"],"gpt_icon":0},{"id":"2476350211","title":"A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2476350211","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476350211?lang=zh_cn&edition=full","pubTime":"2024-10-17 10:22","pubTimestamp":1729131779,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0188","399300","300199","BK0070","688166","600721","301509","BK0077","BK0216","BK0172","BK0239","BK0102","159982","BK0028","300255"],"gpt_icon":0},{"id":"2475334076","title":"翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475334076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475334076?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:21","pubTimestamp":1728894060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司于2024年10月12日收到国家药品监督管理局签发的利拉鲁肽注射液《受理通知书》。该品用于成人2型糖尿病患者控制血糖，适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","300199","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2470256742","title":"翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256742?lang=zh_cn&edition=full","pubTime":"2024-09-25 20:10","pubTimestamp":1727266253,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司收到美国食品药品监督管理局（FDA）的确认，公司司美格鲁肽原料药获得DMF（Drug Master File）备案号。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500031984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0239","BK0077","300199","BK0028"],"gpt_icon":0},{"id":"2470256897","title":"翰宇药业：司美格鲁肽原料药获得DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256897","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256897?lang=zh_cn&edition=full","pubTime":"2024-09-25 20:04","pubTimestamp":1727265848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["DMF","BK0070","BK0239","BK0077","300199","BK0188","BK0028"],"gpt_icon":0},{"id":"2470523761","title":"翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470523761","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470523761?lang=zh_cn&edition=full","pubTime":"2024-09-25 18:50","pubTimestamp":1727261422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司收到美国食品药品监督管理局(FDA)的确认，公司司美格鲁肽原料药获得DMF备案号。司美格鲁肽是一种GLP-1受体激动剂，通过增加胰岛素释放、降低胰高血糖素释放量、延缓胃排空和降低食欲发挥作用。司美格鲁肽用于减轻特定患者的体重，并降低2型糖尿病患者的血糖水平和降低主要心血管事件(如心脏病发作或中风)的风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0188","BK0077","300199","DMF","BK0070"],"gpt_icon":0},{"id":"2468309366","title":"翰宇药业(300199.SZ)：艾塞那肽注射液获批上市 其用于改善2型糖尿病患者的血糖控制","url":"https://stock-news.laohu8.com/highlight/detail?id=2468309366","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468309366?lang=zh_cn&edition=full","pubTime":"2024-09-18 18:17","pubTimestamp":1726654644,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告，近日，公司收到国家药品监督管理局下发的《药品注...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300199","BK0077","BK0028","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2468370944","title":"翰宇药业最新公告：艾塞那肽注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2468370944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468370944?lang=zh_cn&edition=full","pubTime":"2024-09-18 17:01","pubTimestamp":1726650073,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司艾塞那肽注射液获得国家药品监督管理局批准上市，规格分别为5μg和10μg，包装规格为1支/盒，3支/盒。艾塞那肽为GLP-1类似物，用于改善2型糖尿病患者的血糖控制。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091800024018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300199","BK0239","BK0188","BK0070","BK0028"],"gpt_icon":0},{"id":"2465653129","title":"翰宇药业：司美格鲁肽注射液减重三期临床研究方案近日公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2465653129","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465653129?lang=zh_cn&edition=full","pubTime":"2024-09-06 14:22","pubTimestamp":1725603720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["III","BK1583","300199","BK0070","BK0188","BK1576","BK4134","03347","BK0239","BK1141","BK0028","BK0077"],"gpt_icon":0},{"id":"2465456895","title":"翰宇药业：United Bank of Switzerland、Toronto-Dominion Asset Management等多家机构于9月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2465456895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465456895?lang=zh_cn&edition=full","pubTime":"2024-09-05 19:54","pubTimestamp":1725537265,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月5日翰宇药业发布公告称United Bank of Switzerland、Toronto-Dominion Asset Management、Oddo BHF、Grand Alliance Asset Management、U Capital、Sumitomo Mitsui DS Asset Management于2024年9月5日调研我司。公司已与跨国大药企 Hikma 等签订授权合作协议，未来合作订单可持续性强。答：公司司美格鲁肽注射液减重三期临床研究方案，于 2024 年 9月 2 日，在“药物临床试验登记与信息公示平台”首次公示，登记号CTR20243301。是国内首个在体重管理适应症上进入 III 期临床的司美格鲁肽注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500032839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0077","BK0028","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2464932801","title":"翰宇药业：生长抑素原料药获CEP证书 有利于海外市场拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2464932801","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464932801?lang=zh_cn&edition=full","pubTime":"2024-09-04 16:43","pubTimestamp":1725439436,"startTime":"0","endTime":"0","summary":"中国财富通9月4日 - 翰宇药业（300199）公告称，近日，公司的生长抑素原料药收到欧洲药品质量管理局签发的CEP证书（原料药欧洲药典适用性证书），本次生长抑素获得欧洲药品质量管理局签发的CEP证书，为公司的生长抑素原料药进入欧盟市场开拓了准入通道，有利于公司原料药海外市场的拓展，未来将对公司经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=3MJLEKqZ8b0%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEP","300199","BK0070","BK0188","BK0239","BK0028","BK0077"],"gpt_icon":0},{"id":"2464914340","title":"翰宇药业(300199.SZ)：生长抑素原料药获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2464914340","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464914340?lang=zh_cn&edition=full","pubTime":"2024-09-04 16:29","pubTimestamp":1725438545,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司的生长抑素原料药收到欧洲药品质量管理局(以下简称“EDQM”)签发的CEP证书(原料药欧洲药典适用性证书)。生长抑素是人工合成的环状十四氨基酸肽，其与天然生长抑素在化学结构和作用机理上完全相同。生理性生长抑素主要存在于丘脑下部和胃肠道。本次生长抑素获得欧洲药品质量管理局签发的CEP证书，为公司的生长抑素原料药进入欧盟市场开拓了准入通道，有利于公司原料药海外市场的拓展，未来将对公司经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1179182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199","BK0028","CEP","BK0077","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2464361802","title":"先声再明引进第三代ALK抑制剂，步长制药长效 EPO 药物报上市，翰宇药业 GLP1R 激动剂启动肥胖 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2464361802","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464361802?lang=zh_cn&edition=full","pubTime":"2024-09-03 21:08","pubTimestamp":1725368939,"startTime":"0","endTime":"0","summary":"值得注意的是，这是国内首个在肥胖适应症上进入 III 期临床的国产版司美格鲁肽。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409032135149edccb82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409032135149edccb82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300199","BK0077","BK0028","BK0188","BK0196","BK0070","603858","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","stockEarnings":[{"period":"1week","weight":0.0138},{"period":"1month","weight":-0.016},{"period":"3month","weight":0.2936},{"period":"6month","weight":-0.0143},{"period":"1year","weight":-0.267},{"period":"ytd","weight":-0.137}],"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","perCapita":"11874股","boardName":"医药制造业","registeredCapital":"88324万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。","serverTime":1732300186179,"listedPrice":30.19,"stockholders":"59478人(较上一季度减少4.98%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}